Annals of Hematology

, Volume 88, Issue 4, pp 347–350 | Cite as

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

  • Giovanni Palladini
  • Paola Russo
  • Francesca Lavatelli
  • Mario Nuvolone
  • Riccardo Albertini
  • Tiziana Bosoni
  • Vittorio Perfetti
  • Laura Obici
  • Stefano Perlini
  • Remigio Moratti
  • Giampaolo Merlini
Original Article

Abstract

Patients with primary (AL) amyloidosis and heart failure have a very poor prognosis and cannot tolerate aggressive therapy, such as autologous stem cell transplantation and high-dose dexamethasone-based regimens. We prospectively treated 22 patients with advanced cardiac amyloidosis combining oral melphalan, thalidomide, and reduced intensity dexamethasone (MTD). Six patients died due to cardiac amyloidosis before completing cycle 3. Early death was associated with reduced ejection fraction. Eight patients achieved a hematological response and four achieved a durable improvement of cardiac dysfunction. Treatment with MTD is feasible in patients with advanced cardiac AL amyloidosis and effective in subjects with preserved systolic function.

Keywords

Amyloidosis Melphalan Dexamethasone Thalidomide Response 

References

  1. 1.
    Merlini G, Stone MJ (2006) Dangerous small B-cell clones. Blood 108:2520–2530PubMedCrossRefGoogle Scholar
  2. 2.
    Palladini G, Perfetti V, Obici L et al (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936–2938PubMedCrossRefGoogle Scholar
  3. 3.
    Jaccard A, Moreau P, Leblond V et al (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083–1093PubMedCrossRefGoogle Scholar
  4. 4.
    Wechalekar AD, Goodman HJ, Lachmann HJ et al (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:457–464PubMedCrossRefGoogle Scholar
  5. 5.
    Palladini G, Anesi E, Perfetti V et al (2001) A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 113:1044–1046PubMedCrossRefGoogle Scholar
  6. 6.
    Gillmore JD, Goodman HJ, Lachmann HJ et al (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107:1227–1229PubMedCrossRefGoogle Scholar
  7. 7.
    Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751–3757PubMedCrossRefGoogle Scholar
  8. 8.
    Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831PubMedCrossRefGoogle Scholar
  9. 9.
    Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209–1218PubMedCrossRefGoogle Scholar
  10. 10.
    Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328PubMedCrossRefGoogle Scholar
  11. 11.
    Palladini G, Perfetti V, Perlini S et al (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949–2951PubMedCrossRefGoogle Scholar
  12. 12.
    Palladini G, Lavatelli F, Russo P et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854–3858PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Giovanni Palladini
    • 1
  • Paola Russo
    • 1
    • 2
  • Francesca Lavatelli
    • 1
    • 2
  • Mario Nuvolone
    • 1
    • 2
  • Riccardo Albertini
    • 3
  • Tiziana Bosoni
    • 3
  • Vittorio Perfetti
    • 1
    • 2
  • Laura Obici
    • 1
  • Stefano Perlini
    • 2
  • Remigio Moratti
    • 3
  • Giampaolo Merlini
    • 1
  1. 1.Biotechnology Research Laboratories, Center for Amyloidosis, Department of Biochemistry“Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo” and University of PaviaPaviaItaly
  2. 2.Department of Internal Medicine“Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS.) San Matteo” and University of PaviaPaviaItaly
  3. 3.Clinical Chemistry Laboratory“Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo” and University of PaviaPaviaItaly

Personalised recommendations